세계의 파킨슨병 시장 보고서(2025년)

Parkinson´s Disease Global Market Report 2025

US $ 4,490 ￦ 6,183,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 8,938,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,692,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

파킨슨병 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년에는 8.2%의 연평균 복합 성장률(CAGR)로 49억 8,000만 달러에 달할 것으로 예측됩니다. 예측 기간 동안 예상되는 성장은 파킨슨병 증상에 대한 인식 개선, 정부 이니셔티브 강화, 의료비 지출 증가, 파킨슨병 임상시험 수 증가, 유전자 치료의 채택 확대에 의해 이루어질 것으로 예측됩니다. 이 기간의 주요 동향으로는 기술 발전, 정부의 지속적인 노력과 자금 지원, 진단에 인공지능의 통합, 혁신적인 솔루션, 개인 맞춤형 의료로의 전환 등이 있습니다.

신경 퇴행성 질환의 유병률 증가는 파킨슨병 시장의 성장을 가속할 것으로 예측됩니다. 신경 퇴행성 질환은 뇌 및 신경계 뉴런의 진행성 퇴행 및 기능 상실을 특징으로 하는 질환군입니다. 고령화, 유전적 소인, 환경적 영향, 진단의 향상, 만성 건강 상태, 생활습관 변화 등 여러 요인이 이 질환의 유병률 증가에 기여하고 있습니다. 파킨슨병은 신경퇴행성 질환의 근본적인 기전 규명, 잠재적 치료 표적 발굴, 혁신적인 치료법 개발 등 신경퇴행성 질환에 대한 이해를 진전시키는 데 중요한 역할을 하고 있습니다. 예를 들어, 2022년 4월 유럽뇌위원회(European Brain Council)는 600개 이상의 신경질환과 300개에 가까운 정신질환이 전 세계 수백만 명에게 영향을 미치고 있으며, 6,500만 명이 간질로 고통받고 있다고 보고했습니다. 유럽에서만 1,050만 명이 치매를 앓고 있으며, 2050년에는 1,870만 명으로 증가할 것으로 예측됩니다. 결과적으로 신경 퇴행성 질환의 유병률 증가는 파킨슨병 시장 확대에 박차를 가하고 있습니다.

파킨슨병 시장의 주요 기업들은 진행성 파킨슨병 환자의 운동 기능을 강화하고 지속적인 증상 관리를 제공하기 위해 레보도파 기반 치료와 같은 혁신적인 치료 솔루션에 집중하고 있습니다. 레보도파 기반 치료는 뇌에서 도파민으로 전환되는 약물인 레보도파를 사용하여 증상을 완화하고 운동 기능을 개선합니다. 예를 들어, 2024년 10월 미국 바이오 제약사 애브비는 파킨슨병 치료를 위해 설계된 레보도파와 칼비도파를 포함한 병용 요법인 VYALEV의 FDA 승인을 획득했습니다. 이 제제는 레보도파가 뇌에 도달하기 전에 분해되는 것을 방지하여 레보도파의 효능을 높이고 도파민 농도를 증가시킵니다. 떨림, 경직, 서맥 등의 운동 증상을 효과적으로 개선하여 환자의 일상 생활 유지와 삶의 질 향상에 기여합니다. 이 약은 운동 기능의 변동을 경험하는 파킨슨병 환자에게 중요한 치료 솔루션으로 여겨지고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나바이러스 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계 파킨슨병 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업 분석
• 세계의 파킨슨병 시장 : 성장률 분석
• 세계의 파킨슨병 시장 실적 : 규모와 성장, 2019-2024
• 세계의 파킨슨병 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계 파킨슨병 전체 시장(TAM)

제6장 시장 세분화

• 세계의 파킨슨병 시장 : 약제 클래스별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 도파민 작용제
• 카테콜-O-메틸전달효소 억제제
• 모노아민 산화효소 B 억제제
• 항콜린제
• 카르비도파-레보도파
• 기타 약제 클래스
• 세계의 파킨슨병 시장 : 투여 경로별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 경구
• 주사제
• 장내 주입
• 피하
• 기타 투여 경로
• 세계의 파킨슨병 시장 : 유통 채널별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 소매 약국
• 병원 약국
• 온라인 약국
• 세계의 파킨슨병 시장 : 환자 케어 설정별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 클리닉
• 병원
• 세계의 파킨슨병 시장 : 도파민 작용제 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 맥각 유도체
• 비맥각 유도체
• 세계의 파킨슨병 시장 : 카테콜-O-메틸전달효소 억제제 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• Entacapone Tolcapone Opicapone
• 세계의 파킨슨병 시장 : 모노아민 산화효소 B 억제제 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• Selegiline
• Rasagiline
• Safinamide
• 세계의 파킨슨병 시장 : 항콜린제 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• Trihexyphenidyl
• Benztropine
• Procyclidine
• 세계의 파킨슨병 시장 : 카르비도파-레보도파 세분화(유형별), 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 즉방성 제제
• 서방형 제제
• 흡입 및 장내 겔 제제
• 세계의 파킨슨병 시장, 기타 약물 클래스 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 아만타진 및 유도체
• 아데노신 A2A 수용체 길항제
• 글루타민산 길항제

제7장 지역별/국가별 분석

• 세계의 파킨슨병 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 파킨슨병 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 파킨슨병 시장 : 경쟁 구도
• 파킨슨병 시장 : 기업 개요
  • Roche Holding AG : 개요, 제품 및 서비스, 전략 및 재무 분석
  • AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Novo Nordisk A/S : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Takeda Pharmaceutical Company Limited : 개요, 제품 및 서비스, 전략 및 재무 분석
  • UCB S.A. : 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Eisai Co. Ltd.
• Kyowa Kirin Co. Ltd.
• Amneal Pharmaceuticals Inc.
• Neurocrine Biosciences Inc.
• Supernus Pharmaceuticals Inc.
• Sunovion Pharmaceuticals Inc.
• Intracellular Therapies Inc.
• Voyager Therapeutics Inc.
• Sage Therapeutics Inc.
• Adamas Pharmaceuticals Inc.
• Sun Pharma Advanced Research Company Ltd.
• Neuraly Inc.
• Mitsubishi Tanabe Pharma Corporation
• Athira Pharma Inc.
• VistaGen Therapeutics Inc.

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

• 파킨슨병 시장(2029년) : 새로운 기회를 제공하는 국가
• 파킨슨병 시장(2029년) : 새로운 기회를 제공하는 부문
• 파킨슨병 시장(2029년) : 성장 전략
  • 시장 동향에 근거한 전략
  • 경쟁 전략

제36장 부록

LSH

영문 목차

영문목차

Parkinson's disease is a degenerative neurological disorder that impacts movement due to the loss of dopamine-producing cells in the brain. It primarily results in tremors, muscle stiffness, slowed movements, and balance issues. Treatment typically includes medications such as levodopa to manage symptoms, often supplemented with physical therapy and, in some cases, surgical options such as deep brain stimulation.

The main classes of drugs used to treat Parkinson's disease consist of dopamine agonists, catechol-O-methyltransferase inhibitors, monoamine oxidase B inhibitors, anticholinergics, carbidopa-levodopa, and others. Dopamine agonists, for example, mimic dopamine's effects in the brain to help control symptoms. These drugs can be administered via various routes, including oral, injectable, intestinal infusion, subcutaneous, and other methods, depending on treatment requirements. Additionally, the distribution channels for Parkinson's disease medications include retail pharmacies, hospital pharmacies, and online pharmacies, ensuring broad accessibility. Most patient care for Parkinson's disease is managed in clinics and hospitals, where healthcare professionals can closely monitor and treat the condition.

The parkinson's disease market research report is one of a series of new reports from The Business Research Company that provides parkinson's disease market statistics, including parkinson's disease industry global market size, regional shares, competitors with a parkinson's disease market share, detailed parkinson's disease market segments, market trends and opportunities, and any further data you may need to thrive in the parkinson's disease industry. This parkinson's disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The parkinson's disease market size has grown strongly in recent years. It will grow from $3.34 billion in 2024 to $3.63 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth during the historic period can be attributed to the increase in research and development, a rise in government funding, the expansion of personalized treatment plans, the growth of support networks for Parkinson's disease patients, and the increased use of advanced rehabilitation therapies.

The parkinson's disease market size is expected to see strong growth in the next few years. It will grow to $4.98 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth projected for the forecast period is driven by increased awareness of Parkinson's disease symptoms, enhanced government initiatives, rising healthcare spending, a growing number of clinical trials for Parkinson's disease, and greater adoption of gene therapies. Key trends during this period include technological advancements, continued government initiatives and funding, the integration of artificial intelligence in diagnosis, innovative solutions, and a move toward personalized medicine.

The increasing prevalence of neurodegenerative diseases is expected to drive the growth of the Parkinson's disease market. Neurodegenerative diseases are a group of disorders characterized by the progressive degeneration and loss of function of neurons in the brain and nervous system. Several factors contribute to the rising prevalence of these conditions, including an aging population, genetic predisposition, environmental influences, improved diagnosis, chronic health conditions, and lifestyle changes. Parkinson's disease plays a crucial role in advancing the understanding of neurodegenerative diseases by offering insights into their underlying mechanisms, identifying potential therapeutic targets, and developing innovative treatment approaches. For instance, in April 2022, the European Brain Council reported that over 600 neurological diseases and nearly 300 psychiatric conditions affect millions globally, with 65 million people suffering from epilepsy. In Europe alone, 10.5 million people have dementia, with projections indicating an increase to 18.7 million by 2050. As a result, the rising prevalence of neurodegenerative diseases is fueling the expansion of the Parkinson's disease market.

Leading companies in the Parkinson's disease market are focusing on innovative treatment solutions, such as levodopa-based therapy, to enhance motor function and provide continuous symptom management for patients with advanced Parkinson's disease. Levodopa-based therapy involves using levodopa, a medication that converts into dopamine in the brain, to alleviate symptoms and improve motor function. For example, in October 2024, AbbVie Inc., a U.S.-based biopharmaceutical company, received FDA approval for VYALEV, a combination therapy containing levodopa and carbidopa designed for treating Parkinson's disease. This formulation enhances the efficacy of levodopa by preventing its breakdown before reaching the brain, thereby increasing dopamine levels. The medication effectively manages motor symptoms such as tremors, rigidity, and bradykinesia, helping patients maintain daily activities and improving their quality of life. It is considered a key therapeutic solution for patients with Parkinson's disease experiencing motor fluctuations.

In August 2024, AbbVie Inc. expanded its neuroscience portfolio by acquiring Cerevel Therapeutics Holdings Inc., a US-based biotechnology company specializing in treatments for Parkinson's disease. This acquisition aims to strengthen AbbVie's position in addressing unmet medical needs in psychiatric and neurological disorders, reinforcing its commitment to developing innovative therapies for neurodegenerative diseases.

Major players in the parkinson's disease market are Roche Holding AG, AbbVie Inc., Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, UCB S.A., Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Amneal Pharmaceuticals Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc., Sunovion Pharmaceuticals Inc., Intracellular Therapies Inc., Voyager Therapeutics Inc., Sage Therapeutics Inc., Adamas Pharmaceuticals Inc., Sun Pharma Advanced Research Company Ltd., Neuraly Inc., Mitsubishi Tanabe Pharma Corporation, Athira Pharma Inc., VistaGen Therapeutics Inc.

North America was the largest region in the parkinson's disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in parkinson's disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the parkinson's disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The parkinson's disease market consists of revenues earned by entities providing services such as speech therapy, and physical therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The parkinson's disease market also includes sales of amantadine and adenosine A2A receptor antagonists. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Parkinson's Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on parkinson's disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for parkinson's disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The parkinson's disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Dopamine Agonists; Catechol-O-Methyltransferase Inhibitors; Monoamine Oxidase B Inhibitors; Anticholinergics; Carbidopa-Levodopa; Other Drug Classes
• 2) By Route Of Administration: Oral; Injectable; Intestinal infusion; Subcutaneous; Other Route Of Administrations
• 3) By Distribution Channel: Retail Pharmacies; Hospital Pharmacies; Online Pharmacies
• 4) By Patient Care Setting: Clinics; Hospitals
• Subsegments:
• 1) By Dopamine Agonists: Ergot Derivatives; Non-Ergot Derivatives
• 2) By Catechol-O-Methyltransferase (COMT) Inhibitors: Entacapone; Tolcapone; Opicapone
• 3) By Monoamine Oxidase B (MAO-B) Inhibitors: Selegiline; Rasagiline; Safinamide
• 4) By Anticholinergics: Trihexyphenidyl; Benztropine; Procyclidine
• 5) By Carbidopa-Levodopa: Immediate-Release Formulation; Extended-Release Formulation; Inhaled And Intestinal Gel Formulations
• 6) By Other Drug Classes: Amantadine And Derivatives; Adenosine A2A Receptor Antagonists; Glutamate Antagonists
• Companies Mentioned:Roche Holding AG; AbbVie Inc.; Novo Nordisk A/S; Takeda Pharmaceutical Company Limited; UCB S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Parkinson's Disease Market Characteristics

3. Parkinson's Disease Market Trends And Strategies

4. Parkinson's Disease Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Parkinson's Disease Growth Analysis And Strategic Analysis Framework

• 5.1. Global Parkinson's Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Parkinson's Disease Market Growth Rate Analysis
• 5.4. Global Parkinson's Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Parkinson's Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Parkinson's Disease Total Addressable Market (TAM)

6. Parkinson's Disease Market Segmentation

• 6.1. Global Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dopamine Agonists
• Catechol-O-Methyltransferase Inhibitors
• Monoamine Oxidase B Inhibitors
• Anticholinergics
• Carbidopa-Levodopa
• Other Drug Classes
• 6.2. Global Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Intestinal infusion
• Subcutaneous
• Other Route Of Administrations
• 6.3. Global Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• 6.4. Global Parkinson's Disease Market, Segmentation By Patient Care Setting, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinics
• Hospitals
• 6.5. Global Parkinson's Disease Market, Sub-Segmentation Of Dopamine Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ergot Derivatives
• Non-Ergot Derivatives
• 6.6. Global Parkinson's Disease Market, Sub-Segmentation Of Catechol-O-Methyltransferase (COMT) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Entacapone
• Tolcapone
• Opicapone
• 6.7. Global Parkinson's Disease Market, Sub-Segmentation Of Monoamine Oxidase B (MAO-B) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Selegiline
• Rasagiline
• Safinamide
• 6.8. Global Parkinson's Disease Market, Sub-Segmentation Of Anticholinergics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Trihexyphenidyl
• Benztropine
• Procyclidine
• 6.9. Global Parkinson's Disease Market, Sub-Segmentation Of Carbidopa-Levodopa, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immediate-Release Formulation
• Extended-Release Formulation
• Inhaled And Intestinal Gel Formulations
• 6.10. Global Parkinson's Disease Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Amantadine And Derivatives
• Adenosine A2A Receptor Antagonists
• Glutamate Antagonists

7. Parkinson's Disease Market Regional And Country Analysis

• 7.1. Global Parkinson's Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Parkinson's Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Parkinson's Disease Market

• 8.1. Asia-Pacific Parkinson's Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Parkinson's Disease Market

• 9.1. China Parkinson's Disease Market Overview
• 9.2. China Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Parkinson's Disease Market

• 10.1. India Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Parkinson's Disease Market

• 11.1. Japan Parkinson's Disease Market Overview
• 11.2. Japan Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Parkinson's Disease Market

• 12.1. Australia Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Parkinson's Disease Market

• 13.1. Indonesia Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Parkinson's Disease Market

• 14.1. South Korea Parkinson's Disease Market Overview
• 14.2. South Korea Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Parkinson's Disease Market

• 15.1. Western Europe Parkinson's Disease Market Overview
• 15.2. Western Europe Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Parkinson's Disease Market

• 16.1. UK Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Parkinson's Disease Market

• 17.1. Germany Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Parkinson's Disease Market

• 18.1. France Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Parkinson's Disease Market

• 19.1. Italy Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Parkinson's Disease Market

• 20.1. Spain Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Parkinson's Disease Market

• 21.1. Eastern Europe Parkinson's Disease Market Overview
• 21.2. Eastern Europe Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Parkinson's Disease Market

• 22.1. Russia Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Parkinson's Disease Market

• 23.1. North America Parkinson's Disease Market Overview
• 23.2. North America Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Parkinson's Disease Market

• 24.1. USA Parkinson's Disease Market Overview
• 24.2. USA Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Parkinson's Disease Market

• 25.1. Canada Parkinson's Disease Market Overview
• 25.2. Canada Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Parkinson's Disease Market

• 26.1. South America Parkinson's Disease Market Overview
• 26.2. South America Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Parkinson's Disease Market

• 27.1. Brazil Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Parkinson's Disease Market

• 28.1. Middle East Parkinson's Disease Market Overview
• 28.2. Middle East Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Parkinson's Disease Market

• 29.1. Africa Parkinson's Disease Market Overview
• 29.2. Africa Parkinson's Disease Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Parkinson's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Parkinson's Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Parkinson's Disease Market Competitive Landscape And Company Profiles

• 30.1. Parkinson's Disease Market Competitive Landscape
• 30.2. Parkinson's Disease Market Company Profiles
  • 30.2.1. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. UCB S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Parkinson's Disease Market Other Major And Innovative Companies

• 31.1. Eisai Co. Ltd.
• 31.2. Kyowa Kirin Co. Ltd.
• 31.3. Amneal Pharmaceuticals Inc.
• 31.4. Neurocrine Biosciences Inc.
• 31.5. Supernus Pharmaceuticals Inc.
• 31.6. Sunovion Pharmaceuticals Inc.
• 31.7. Intracellular Therapies Inc.
• 31.8. Voyager Therapeutics Inc.
• 31.9. Sage Therapeutics Inc.
• 31.10. Adamas Pharmaceuticals Inc.
• 31.11. Sun Pharma Advanced Research Company Ltd.
• 31.12. Neuraly Inc.
• 31.13. Mitsubishi Tanabe Pharma Corporation
• 31.14. Athira Pharma Inc.
• 31.15. VistaGen Therapeutics Inc.

32. Global Parkinson's Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Parkinson's Disease Market

34. Recent Developments In The Parkinson's Disease Market

35. Parkinson's Disease Market High Potential Countries, Segments and Strategies

• 35.1 Parkinson's Disease Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Parkinson's Disease Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Parkinson's Disease Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료